In 2005, RNAi Science Advances and Big Pharma Takes Notice; As Usual, More Work Left to Be Done | GenomeWeb

In the nascent RNAi therapeutics field, getting recognition from well-established industry players has proven to be perhaps the most important piece of the overall business puzzle. Aside from the upfront revenue a big pharma/biotech alliance can bring, the investment community often sees a nod from a large company as one of the best indications of a firm's health since a business partner is privy to scientific and corporate information not available to the public.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Biomedical research projects are generating a ton of data that still needs to be analyzed, NPR reports.

Theranos is retiring some of its board members, including Henry Kissinger and George Shultz, Business Insider reports.

The heads of 29 scientific societies and some 2,300 researchers call on President-elect Donald Trump to rely on and support science in two separate letters.

In Science this week: genetically modified flu virus could be key to new live vaccines, and more.